Union Therapeutics A/s

Antibiotx A/s

Daniel Jean Jacques Simon

Morten Otto Alexander Sommer

Rasmus Vendler Toft-Kehler

Emilie Flora Aurore Delavenne

Ramus Vendler Toft-Kehler

The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused bybacteria, particularly ainfection. The halogenated salicylanilides are expected to be useful in the treatment ofassociated diseases includingassociated diarrhoea andassociated colitis.

Halogenated salicylanilides for treatinginfections

The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as, in particular, and, in particular. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.

Antibacterial use of halogenated salicylanilides

The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such asin particularandin particularGrain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.

The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as, in particular, and, in particularGrain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.

The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused bybacteria, particularly ainfection. The halogenated salicylanilides are expected to be useful in the treatment ofassociated diseases includingassociated diarrhea andassociated colitis.

Halogenated salicylanilides for treating clostridium infections

The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as, in particular, and, in particular. Gram positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.

Growing community of inventors

Søborg, Denmark

Daniel Jean Jacques Simon